NASDAQHealth CareInsurance - BrokersSnapshot 2026-10-23
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
A matching fiscal period and sufficient coverage are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Expansion of CERIS prepay solutions | The company expands its CERIS prepay solutions. | Intact | CERIS solution expansion stalls or reverses | Qualitative: Robust growth reported May 2026 earnings call transcript confirms robust growth, reinforcing the expansion of CERIS prepay solutions. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Free cash flow yield near 3% | Free cash flow yield is steady near 3%. | Intact | Free cash flow yield falls below 3% | Free cash flow yield: 2.66% As of 2026-10-23; trailing twelve months. The target timing and basis require a separate assessment. Market data as of Oct 23, 20262.66 percent · calculatedLast status assessment Oct 24, 2026Measurement sourceconsolidated · TTM valuation Period ending Oct 23, 2026 Source: mart.stock_valuation_daily. Reference: CRVL:2026-10-23. Source status: canonical calculation. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Profit margins remain stable near current levels | Profit margins stay stable. | Improving | Profit margins decline significantly below recent levels | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth at or above 7% annually | A primary condition in CorVel Corporation's published investment case. The stated target is >=7% YoY. | Intact | YoY revenue growth falls below 7% next year | Revenue growth: 0% FY2027-Q1; GAAP. Published target: >=7% YoY. Target period is not explicitly aligned with this observation. Source published Aug 6, 20260 percent · calculatedSource reportLast status assessment Oct 24, 2026Measurement sourceconsolidated · GAAP FY2027-Q1 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 18bc7241-97ba-4e60-8bc8-df4ea4abd47b. Source status: unverified. Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Sep 25–Oct 24 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 3, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a service-business growth thesis with a durable valuation premium, rather than a turnaround. The long-term thesis is intact, though near-term earnings risk is elevated and the evidence snapshot carries medium confidence.
CRVL trades at a premium to peers, reflecting expectations that its business strengths can persist. The expectations gap is meaningful, and the evidence labels that premium unjustified, but it does not identify a broader stack of expensive valuation, weak fundamentals, and turbulence.
In the near term, consecutive earnings misses and a 43% estimated chance of another miss make the next report a key test. Over the multi-year view, CERIS prepay revenue has grown, P&C services have advanced, and management continues to prioritize AI and automation, although progress on that priority bears watching.
The next guidance update and the jobs trend are near-term swing factors: weaker guidance or continued labor-market weakness could pressure cyclical businesses, including healthcare names. Over the multi-year view, the thesis depends on continued delivery in CERIS and P&C, progress in AI and automation, and support from healthcare-sector earnings.
The 1-to-3-year thesis remains intact, with strong recent performance and service-line progress offset by elevated earnings risk and a premium valuation. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.